About: Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayo clínico (es) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) (en)
skos:prefLabel	Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) (en)
name	Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) (en)
title	wds:Q61980614-36E0CC7E-7036-448B-A09D-A9F82A189167
title	An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus (en)
end time	wds:Q61980614-CF4E6358-9A81-40D6-83AA-D6A4458F6818
end time	2011-02-01 00:00:00Z (xsd:dateTime)
instance of	wds:Q61980614-4C517156-3691-413E-9054-87B5BB85CB49
instance of	clinical trial
start time	wds:Q61980614-06BCC8CE-57FD-4708-BE4B-5736E979AD81
start time	2009-02-01 00:00:00Z (xsd:dateTime)
country	wds:Q61980614-F8D9FDC8-D890-41D9-9915-175858688AE2
country	United States of America
research site	wds:Q61980614-A248FE20-88D8-436D-B6E9-C8DCE4554565
research site	Atlanta Diabetes Associates
minimum age	wds:Q61980614-9AD5C69B-5CDD-4608-BC1E-6F7FB42456AF
minimum age	10 (xsd:decimal)
medical condition	wds:Q61980614-3CA08DFB-5611-4E0C-AAC6-D0960E3322D5
sponsor	wds:Q61980614-70E4965C-3B37-4AAF-AE7A-AE941CD314C5
medical condition	diabetes
sponsor	MacroGenics (United States)
number of participants	wds:Q61980614-A4BD5C29-142E-4069-944A-09658D07DC1B
number of participants	219 (xsd:decimal)
maximum age	wds:Q61980614-BBFF4E62-6EAD-4EB3-984B-6FBA7CCA19F5
maximum age	37 (xsd:decimal)
study type	wds:Q61980614-982CBBC6-F62E-4714-88C7-4D5AED2C34C2
study type	interventional study
ClinicalTrials.gov ID	wds:Q61980614-ED80B746-D28C-4D11-9B45-9525560BC6CF
ClinicalTrials.gov ID	NCT00870818
clinical trial phase	wds:Q61980614-2C811A57-43EC-4F53-9C51-34F1247C3F9E wds:Q61980614-CAD90F05-3BCC-4B06-9591-CE70F4550DC8
clinical trial phase	phase III clinical trial phase II clinical trial
research subject recruitment status	wds:Q61980614-2D3DE85A-579D-4F75-98AF-3F9D4A82FFD7
research subject recruitment status	terminated
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q61980614

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software